EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
[HTML][HTML] Current therapy and drug resistance in metastatic castration-resistant prostate cancer
M Cai, XL Song, XA Li, M Chen, J Guo, DH Yang… - Drug Resistance …, 2023 - Elsevier
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)–European Society for Radiotherapy & Oncology (ESTRO)–International Society of …
(EAU)–European Society for Radiotherapy & Oncology (ESTRO)–International Society of …
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a …
Background Abiraterone acetate plus prednisone or prednisolone improves progression-
free survival and overall survival in patients with metastatic castration-resistant prostate …
free survival and overall survival in patients with metastatic castration-resistant prostate …
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …
genomic landscapes and biological functions, the treatment of PCa continues to improve …
Novel approaches to target the microenvironment of bone metastasis
Bone metastases are a frequent and severe complication of advanced-stage cancers. Breast
and prostate cancers, the most common malignancies in women and men, respectively …
and prostate cancers, the most common malignancies in women and men, respectively …
Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer
During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …
Epidemiology, staging and management of prostate cancer
Prostate cancer is the second most common and fifth most aggressive neoplasm among
men worldwide. It is particularly incident in high human development index (HDI) nations …
men worldwide. It is particularly incident in high human development index (HDI) nations …
Molecular mechanisms and clinical management of cancer bone metastasis
M Wang, F **a, Y Wei, X Wei - Bone research, 2020 - nature.com
As one of the most common metastatic sites of malignancies, bone has a unique
microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated …
microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated …
The treatment landscape of metastatic prostate cancer
Y Yamada, H Beltran - Cancer letters, 2021 - Elsevier
The treatment landscape of metastatic prostate cancer has evolved significantly over the
past two decades. Several landmark phase 3 trials led to new drug approvals and rapid …
past two decades. Several landmark phase 3 trials led to new drug approvals and rapid …